Improved chemotherapy for hepatocellular carcinoma

Anticancer Research

Volumn 32, Issue 4, 2012, Pages 1379-1386

  Cao, Huynh ^a   Phan, Hung ^a   Yang, Li Xi ^a,b  

^a ST MARY S MEDICAL CENTER   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Combined therapy; Hepatocellular carcinoma; Monotherapy; New targeted therapy; Novel anticancer agents; Review; Sorafenib

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BAY 86 9766; BEVACIZUMAB; BRIVANIB; BUFALIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DEFEROXAMINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; LAPATINIB; LINIFANIB; MAPATUMUMAB; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; ORANTINIB; PACLITAXEL; PERETINOIN; PI 88; PLACEBO; SELUMETINIB; SORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CHEMOEMBOLIZATION; DIARRHEA; DRUG EFFICACY; FATIGUE; HUMAN; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS;

EID: 84859973897     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. El-Serag HB and Rudolph KL: Gastroenterology 132: 2557-2576, 2007.
2. Park KW, Park JW, Choi JI, Kim TH, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK and Kim CM: Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 23: 467-473, 2008. (Pubitemid 351342066)
3. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A and Johnson PJ: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97: 1532-1538, 2005. (Pubitemid 41631953)
4. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both RAF and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140, 2008.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, De Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
6. Kim HY and Park JW: Molecularly targeted therapies for hepatocellular carcinoma: Sorafenib as a stepping stone. Digest Dis 29: 303-309, 2011.
7. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS, Rafii S and Schwartz JD: Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26: 2992-2998, 2008.
8. Alberts SR, Fitch TR, Kim GP, Morlan BW, Dakhil SR, Gross HM and Nair S: Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: A phase II North Central Cancer Treatment Group clinical trial. Am J Clin Oncol, 2011.
9. Blum R, Cox AD and Kloog Y: Inhibitors of chronically active RAS: Potential for treatment of human malignancies. Recent Pat Anticancer Drug Discov 3: 31-47, 2008. (Pubitemid 351223208)
10. Avruch J: Insulin signal transduction through protein kinase cascades. Mol Cell Biochem 182: 31-48, 1998.
11. O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM and Sullivan DM: Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma. Clini Oncol 29: 2350-2356, 2011.
12. Huynh H, Chow KH, Soo KC, Toh HC, Choo SP, Foo KF, Poon D, Ngo VC and Tran E: RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 13: 1371-1380, 2009.
13. Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR and Ryan DP: Phase 1/2 Study of Everolimus in Advanced Hepatocellular Carcinoma. Cancer 117: 5094-5102, 2011.
14. Yu Y, Kovacevic Z and Richardson DR: Tuning cell cycle regulation with an iron key. Cell Cycle 6: 1982-1994, 2007. (Pubitemid 47327885)
15. Yamasaki T and Terai S: Deferoxamine for Advanced Hepatocellular Carcinoma. N Engl J Med 365: 576-577, 2011.
16. Muto Y, Moriwaki H and Omori M: In vitro binding affinity of novel synthetic polyprenoids (polyprenoic acids) to cellular retinoid-binding proteins. Gann 72: 974-977, 1981. (Pubitemid 12172470)
17. Muto Y, Moriwaki H and Shiratori Y: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 334: 1561-7, 1996. (Pubitemid 26177483)
18. Okusaka T, Ueno H, Ikeda M and Morizane C: Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333. Hepatol Res 41: 542-552, 2011.
19. Gao Y, Li HX, Xu LT, Wang P, Xu LY, Cohen L, Yang PY, Gu K and Meng ZQ: Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through down-regulation of ERK. Mol Biol Rep 39: 1683-1689, 2011.
20. Piguet AC, Saar B, Hlushchuk R, St-Pierre MV, McSheehy PM, Radojevic V, Afthinos M, Terracciano L, Djonov V and Dufour JF: Everolmus augments the effects of sorafeib in a syneneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther 10: 1007-1016, 2011.
21. Kuo T and Lu H: The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. Biochem Pharmacother 82: 184-194, 2011.
22. Sasaki S, Ishida T, Toyota M, Ota A, Suzuki H, Takaoka A, Yasui H, Yamamoto H, Takagi H, Maeda M, Seito T, Tsujisaki M, Shinomura Y and Imai K: Interferon α/β and antifibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cell in vitro and in vivo. Plos one 6(5): e19618, 2011.
23. Tomuleasa C, Soritau O, Fischer-Fodor E, Pop T, Susman S, Mosteanu O, Petrushev B, Aldea M, Acalovschi M, Irimie A, and Kacso G: Arsenic trioxide plus cisplatin/interferon a-2b/ doxorubicin/ capecitabine combination chemotherapy for unrecectable hepatocellular carcinoma. Hematol Oncol Stem Cell Ther 4: 60-65, 2011.
24. Alberts SR, Reid JM, Morlan BW, Farr GH, Camoriano JK, Johnson DB, Enger JR, Seay TE and Kim GP: Gemcitabine and docetaxel for hepatocellular carcinoma, a phase II north central cancer treatment group clinical trial. Am J Clini Oncol 2011.
25. Sun W, Sohal D, Haller DG, Mykulowycz K, Rosen M, Soulen MC, Caparro M, Teitelbaum UR, Giantonio B, O'Dwyer PJ, Shaked A, Reddy R and Olthoff K: Phase II trial of bevacimumab, capecitabine and oxaliptan in treatment of advanced hepatocellular carcinoma; Cancer 117: 3187-3188, 2011.
26. Lee SJ, Lee J, Park SH, Park JO, Park YS, Kang WK, Lee J, Yim DS and Lim HY: Phase I trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. Invest new drugs 3, 2011.
27. Ma PC, Maulik G, Christensen J and Salgia R: c-MET: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 22: 309-325, 2008.
28. Inagaki Y, Qi F, Gao J, Qu X, Hasegawa K, Sugawara Y, Tang W and Kokudo N: Effect of c-MET inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci Trends 5(2): 52-56, 2011.
29. You H, Ding W, Dang H, Jiang Y and Rountree CB: c-MET represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 54: 879-889, 2011.
30. Murata M, Matsuzaki K, Yoshida K, Sekimoto G, Tahashi Y, Mori S, Uemura Y, Sakaida N, Fujisawa J, Seki T, Kobayashi K, Yokote K, Koike K and Okazaki K: Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology 49: 1203-1217, 2009.
31. Xu J, Lamouille S and Derynck R: TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172, 2009.
32. Baek HJ, Pishvaian MJ, Tang Y, Kim TH, Yang S, Zouhairi ME, Mendelson J, Shetty K, Kallakury B, Berry DL, Shin KH, Mishra B, Reddy EP, Kim SS and Mishra L: Transforming growth factor-B adaptor, B2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer. Hepatology 53: 1676-1684, 2011.
33. Wu J, Ru NY, Zhang Y, Li Y, Wei D, Ren Z, Huang XF, Chen ZN and Bian H: HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-B signaling and is transcriptionally regulated by Slug. Oncogene 30: 4410-4427, 2011.
34. Tai DI, Tsai SL, Chang YH, Huang SN, Chen TC, Chang KS and Liaw YF: Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer 89: 2274-2281, 2000.
35. Freise C, Ruehl M, Erben U, Neumann U, Seehofer D, Kim KY, Trowitzsch-Kienast W, Stroh T, Zeitz M and Somasundaram R: A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines. BMC Compl Altern Med 11: 39, 2011.
36. Khan MS, Halagowder D and Devaraj SN: Methylated chrysin induces co-ordinated attenuation of the canonical Wnt and NF-kB signaling pathway and upregulates apoptotic gene expression in the early hepatocarcinogenesis rat model. Chem Biol Interact 193: 12-21, 2011.
37. Xiao CL, Tao ZH, Guo L, Li WW, Wan JL, Sun HC, Wang L, Tang ZY, Fan J and Wu WZ: Isomalto oligosaccharide sulfate inhibits tumor growth and metastasis of hepatocellular carcinoma in nude mice. BMC Cancer 11: 150, 2011.
38. Amin A, Hamza AA, Bajbouj K, Ashraf SS and Daoud S: Saffron: a potential candidate for a novel anticancer drug against heptocellular carcinoma. Hepatology 54: 857-867, 2011.
39. Liu W, Xu G, Ma J, Jia W, Li J, Chen K, Wang W, Hao C, Wang Y and Wang X: Osteopontin as a key mediator for vasculogenic mimicry in hepatocellular carcinoma. Tohoku J Exp Med 244: 29-39, 2011.
40. Lai L and Ho T: Pigment epithelial-derived factor inhibits c-FLIP expression and assists ciglitazone-induced apoptosis in hepatocellular carcinoma. Anticancer Res 31: 1173-1180, 2011.
41. Mazzocca A, Dituri F, Lupo L, Quaranta M, Antonaci S and Giannelli G: Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts. Hepatology 54: 920-930, 2011.
42. Huang XH, Chen JS, Wang Q, Chen XL, Wen L, Chen LZ, Bi J, Zhang LJ, Su Q and Zeng WT: miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J Pathol 225: 463-472, 2011.
43. Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, Kung HF and Xie D: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 61(2): 278-89, 2012.
44. Cohen S, Stemmer SM, Zozulya G, Ochaion A, Patoka R, Barer F, Bar-Yehuda S, Rath-Wolfson L, Jacobson KA and Fishman P: CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol 226(9): 2438-2447, 2011.
45. Zhang ZF, Guo Y, Zhang JB and Wei XH: Induction of apoptosis by chelerythrine chloride through mitochondrial pathway and BCL-2 family proteins in human hepatoma SMMC-7721 cell. Arch Pharm Res 34: 791-800, 2011.
46. Liu ZM, Tseng JT, Hong DY and Huang HS: Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells. Biochem J 438: 349-358, 2011.
47. Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z, Liu J, Cui Y, Bian X, Bie P and Qian C: MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 310: 160-169, 2011.
48. Song XD, Zhang JJ, Wang MR, Liu WB, Gu XB and Lv CJ: Astaxanthin induces mitochondria-mediated apoptosis in rat hepatocellular carcinoma CBRH-7919 cells. Biol Pharm 34: 839-844, 2011.
49. Yang L, Ling Y, Zhang Z, Zhao Q, Tang J, Ji H and Zhang Y: ZL11n is a novel nitric oxide-releasing derivative of farnesylthiosalicylic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways. Biochem Biophys Res Commun 409: 752-757, 2011.
50. Sun JG, Chen CY, Luo KW, Yeung CL, Tsang TY, Huang ZZ, Wu P, Fung KP, Kwok TT and Liu FY: 3,5-Dimethyl-H-Furo[3,2-g]chromen-7-one as a potential anticancer drug by inducing p53-dependent apoptosis in human hepatoma HepG2 cells. Chemotherapy 57: 162-172, 2011.
51. Carlisi D, D'Anneo A, Angileri L, Lauricella M, Emanuele S, Santulli A, Vento R and Tesoriere G: Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. J Cell Physiol 226(6): 1632-41, 2011.
52. Wolfe A, Thomas A, Edwards G, Jaseja R, Guo GL and Apte U: Increased Activation of the Wnt/ β-Catenin pathway in spontaneous hepatocellular carcinoma observed in fernesoid x receptor knockout mice. J Pharmacol Exp Ther 338: 12-21, 2011.
53. Choi MJ, Jung KH, Kim D, Lee H, Zheng HM, Park BH, Hong SW, Kim MH, Hong S and Hong SS: Anticancer effects of a novel compound HS-113 on cell growth, apoptosis, and angiogenesis in human hepatocellular carcinoma cells. Cancer Lett 306: 190-196, 2011.
54. Yin H, Xie F, Zhang J, Yang Y, Deng B, Sun J, Wang Q, Qu X and Mao H: Combination of interferon-alpha and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. Cancer Lett 306: 34-42, 2011.
55. Chen C, Zhang Y, Wang Y, Huang D, Xi Y and Qi Y: Synergic effect of 3′-azido-3′-deoxythymidine and arsenic trioxide in suppressing hepatoma cells. Anticancer Drugs 22: 435-443, 2011.
56. Cho SJ, Kim YJ, Surh YJ, Kim BM and Lee SK: Ibulocydine is a novel prodrug CDK inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells. J Biol Chem 286: 1966219671, 2011.
57. Liu Y, Liu A, Li H, Li C and Lin J: Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT 3 phosphrylation in human hepatocellular carcinoma cells. Cancer Prev Res 4(8): 1296-305, 2011.
58. Vara D, Salazar M, Olea-Herrero N, Guzmán M, Velasco G and Díaz-Laviada I: Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ 18: 1099-1111, 2011.
59. Chiu YW, Lin TH, Huang WS, Teng CY, Liou YS, Kuo WH, Lin WL, Huang HI, Tung JN, Huang CY, Liu JY, Wang WH, Hwang JM and Kuo HC: Baicalein inhibits the migration and invasive properties of human hepatoma cells. Toxicol Appl Pharmacol 255: 316-326, 2011.
60. Zhao X, Ogunwobi OO and Liu C: Survivin inhibition is critical for BCL-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells. Plos One 6(8): e21980, 2011.
61. Sasaki S, Ishida T, Toyota M, Ota A, Suzuki H, Takaoka A, Yasui H, Yamamoto H, Takagi H, Maeda M, Seito T, Tsujisaki M, Shinomura Y and Imai K: Interferon-alpha/beta and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo. Plos One 6(5): e19618, 2011.
62. Zheng S, Chang S, Lu J, Chen Z, Xie L, Nie Y, He B, Zou S and Gu Z: Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo. Plos One 6(6): e21064, 2011.
63. Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Ahn KS, Kumar AP and Sethi G: Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. Journal of Cellular Physiology 227(5): 2184-2195, 2012.
64. Chen TA, Wang JL, Hung SW, Chu CL, Cheng YC and Liang SM: Recombinant VPl, an AKT inhibitor, suppresses progression of hepatocellular carcinoma by inducing apoptosis and modulation of CCL2 production. Plos One 6(8): e23317, 2011.
65. Liu C, Gong K, Mao X and Li W: Tetrandrine induces apoptosis by activating reactive oxygen species and repressing AKT activity in human hepatocellular carcinoma. Int J Cancer 129: 1519-1531, 2011.